Jeffrey D Ritzenthaler1, Michael Zhang2,3, Edilson Torres-Gonzalez4, Jesse Roman2,5,4,6. 1. Department of Medicine, Division of Pulmonary, Allergy and Critical Medicine, Jane & Leonard Korman Respiratory Institute, Thomas Jefferson University, Jefferson Alumni Hall, 381, Philadelphia, PA, 19107, USA. jeffrey.ritzenthaler@jefferson.edu. 2. Department of Pharmacology & Toxicology, University of Louisville Health Sciences Center, Louisville, KY, USA. 3. University of Minnesota Medical School, Minneapolis, MN, USA. 4. Department of Medicine, Division of Pulmonary, Allergy and Critical Medicine, Jane & Leonard Korman Respiratory Institute, Thomas Jefferson University, Jefferson Alumni Hall, 381, Philadelphia, PA, 19107, USA. 5. Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Louisville Health Sciences Center, Louisville, KY, USA. 6. Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Abstract
PURPOSE: Fibroproliferation and excess deposition of extracellular matrix (ECM) are the pathologic hallmarks of idiopathic pulmonary fibrosis (IPF), a chronic progressive disorder with high mortality and suboptimal treatment options. Although the etiologic mechanisms responsible for the development and progression of IPF remain unclear, cell-ECM interactions and growth factors are considered important. Cilengitide is a cyclic RGD pentapeptide with anti-angiogenic activity that targets αvβ3, αvβ5 and α5β1, integrins known to mediate cell-ECM interactions and activate the pro-fibrotic growth factor Transforming Growth Factor beta (TGF-β). METHODS: Cilengitide was studied in vitro with the use of NIH/3T3 cells and primary lung fibroblasts, and in vivo in the well-characterized bleomycin-induced lung injury model. The extent of ECM deposition was determined by RT-PCR, Western blot, histologic analysis and hydroxyproline assay of lung tissue. Bronchoalveolar lavage analysis was used to determine cell counts. RESULTS: Cilengitide treatment of cultured fibroblasts showed decreased adhesion to vitronectin and fibronectin, both integrin-dependent events. Cilengitide also inhibited TGF-β-induced fibronectin gene expression and reduced the accumulation of mRNAs and protein for fibronectin and collagen type I. Both preventive and treatment effects of daily injections of cilengitide (20 mg/kg) failed to inhibit the development of pulmonary fibrosis as determined by histological analysis (Ashcroft scoring), bronchoalveolar lavage (BAL) fluid cell counts, and hydroxyproline content. CONCLUSIONS: Overall, our data suggest that, despite its in vitro activity in fibroblasts, daily injections of cilengitide (20 mg/kg) did not inhibit the development of or ameliorate bleomycin-induced pulmonary fibrosis in mice.
PURPOSE: Fibroproliferation and excess deposition of extracellular matrix (ECM) are the pathologic hallmarks of idiopathic pulmonary fibrosis (IPF), a chronic progressive disorder with high mortality and suboptimal treatment options. Although the etiologic mechanisms responsible for the development and progression of IPF remain unclear, cell-ECM interactions and growth factors are considered important. Cilengitide is a cyclic RGD pentapeptide with anti-angiogenic activity that targets αvβ3, αvβ5 and α5β1, integrins known to mediate cell-ECM interactions and activate the pro-fibrotic growth factor Transforming Growth Factor beta (TGF-β). METHODS: Cilengitide was studied in vitro with the use of NIH/3T3 cells and primary lung fibroblasts, and in vivo in the well-characterized bleomycin-induced lung injury model. The extent of ECM deposition was determined by RT-PCR, Western blot, histologic analysis and hydroxyproline assay of lung tissue. Bronchoalveolar lavage analysis was used to determine cell counts. RESULTS: Cilengitide treatment of cultured fibroblasts showed decreased adhesion to vitronectin and fibronectin, both integrin-dependent events. Cilengitide also inhibited TGF-β-induced fibronectin gene expression and reduced the accumulation of mRNAs and protein for fibronectin and collagen type I. Both preventive and treatment effects of daily injections of cilengitide (20 mg/kg) failed to inhibit the development of pulmonary fibrosis as determined by histological analysis (Ashcroft scoring), bronchoalveolar lavage (BAL) fluid cell counts, and hydroxyproline content. CONCLUSIONS: Overall, our data suggest that, despite its in vitro activity in fibroblasts, daily injections of cilengitide (20 mg/kg) did not inhibit the development of or ameliorate bleomycin-induced pulmonary fibrosis in mice.
Authors: Vincent Sarrazy; Anne Koehler; Melissa L Chow; Elena Zimina; Chen X Li; Hideyuki Kato; Christopher A Caldarone; Boris Hinz Journal: Cardiovasc Res Date: 2014-03-17 Impact factor: 10.787
Authors: Victor J Thannickal; Craig A Henke; Jeffrey C Horowitz; Paul W Noble; Jesse Roman; Patricia J Sime; Yong Zhou; Rebecca G Wells; Eric S White; Daniel J Tschumperlin Journal: Am J Pathol Date: 2014-04-13 Impact factor: 4.307
Authors: Chao Li; Robert S Flynn; John R Grider; Karnam S Murthy; John M Kellum; Homayoon Akbari; John F Kuemmerle Journal: Inflamm Bowel Dis Date: 2013-12 Impact factor: 5.325
Authors: J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard Journal: Cell Date: 1999-02-05 Impact factor: 41.582
Authors: L Burt Nabors; Tom Mikkelsen; Steven S Rosenfeld; Fred Hochberg; Narasimha S Akella; Joy D Fisher; Gretchen A Cloud; Yu Zhang; Kathryn Carson; Sabine M Wittemer; A Dimitrios Colevas; Stuart A Grossman Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544
Authors: Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; Paul F Mercer; Y C Gary Lee; Naftali Kaminski; John Morser; Joseph M Post; Toby M Maher; Andrew G Nicholson; James D Moffatt; Geoffrey J Laurent; Claudia K Derian; Oliver Eickelberg; Rachel C Chambers Journal: J Clin Invest Date: 2009-08-03 Impact factor: 14.808
Authors: Neil C Henderson; Thomas D Arnold; Yoshio Katamura; Marilyn M Giacomini; Juan D Rodriguez; Joseph H McCarty; Antonella Pellicoro; Elisabeth Raschperger; Christer Betsholtz; Peter G Ruminski; David W Griggs; Michael J Prinsen; Jacquelyn J Maher; John P Iredale; Adam Lacy-Hulbert; Ralf H Adams; Dean Sheppard Journal: Nat Med Date: 2013-11-10 Impact factor: 53.440